Drug,Receptor,PDB_ID,generated_report,prompt_tier
Metformin,Acetyl-CoA carboxylase 2,"3FF6,3TDC,2X24,3JRX,3JRW,2HJW,4HQ6,5KKN,3GLK,3GID,2DN8",")<Output>
{{
  ""Mechanism"": ""<Metformin targets acetyl-CoA carboxylase 2 (ACC2) in the glycolytic pathway, which is crucial for cellular energy production. Metformin inhibits ACC2, thereby reducing glycolysis and increasing fatty acid oxidation, which can help mitigate insulin resistance and metabolic syndrome risk factors."",
  ""Pathways"": ""<Metformin affects multiple signaling pathways including AMPK, mTOR, PI3K/AKT, and NF-κB. It also influences the insulin signaling pathway and has been shown to have protective effects against cardiovascular disease and type 2 diabetes."",
  ""Uncertainties"": ""<Metformin's effects on the insulin signaling pathway are less clear. Some studies suggest it may have beneficial effects, but others show no significant benefits. The impact of metformin on cardiovascular disease risk is also unclear.>"",
}}
</Output>

<Previous Knowledge>
- Metformin works by decreasing glucose production in the liver, improving insulin sensitivity, and increasing the body's use of glucose that does come from the food we eat.
- It has been linked to improved cardiovascular health, reduced risk of type 2 diabetes, and potential benefits for certain cancers, including colorectal cancer.
- However, the exact mechanisms through which metformin exerts these effects are complex and involve multiple pathways.
- Uncertainties include the precise mechanisms by which metformin improves cardiovascular health and its effects on cancer risk.
</Previous Knowledge>

<Constraining Information>
- The evidence suggests metformin may have beneficial effects on colorectal cancer risk, although the exact mechanisms are unclear.
- The involvement of AMPK, mTOR, PI3K/AKT, and NF-κB signaling pathways supports this.
- However, more research is needed to fully understand the relationship between metformin and colorectal cancer.
- Uncertainties remain regarding the precise mechanisms through which metformin exerts its effects.
</Constraining Information>

<Following Constraints>
- The evidence suggests metformin may have beneficial effects on colorectal cancer risk, although the exact mechanisms are unclear.
- The involvement of AMPK, mTOR, PI3K/AKT, and NF-κB signaling pathways supports this.
- However, more research is needed to fully understand the relationship between metformin and colorectal cancer.
- Uncertainties remain regarding the precise mechanisms through which metformin exerts its effects.
</Following Constraints>",basic
Pioglitazone,Peroxisome proliferator-activated receptor gamma,"3E00,3DZY,3DZU,7QB1,6L89,6K0T,6AD9,5HZC,5F9B,5DWL,5DVC,5DV8,5DV6,5DV3,5DSH,4PWL,4PVU,4JL4,4JAZ,4E4Q,4E4K,4A4W,4A4V,3R8I,3ADX,3ADW,3ADV,3ADU,3ADT,3ADS,2YFE,8REJ,6ZLY,6T9C,6QJ5,6L8B,6JQ7,6IJR,6F2L,5YCP,5YCN,5LSG,5GTP,5GTO,5GTN,7CXH,7CXG,9HX2,7CXI,4YT1,4O8F,3WMH,3VSP,3VSO,3VJI,3VJH,3HOD,3HO0,3D6D,3CDS,3CDP,3B3K,3AN4,3AN3,2ZNO,2ZK6,2ZK5,2ZK4,2ZK3,2ZK2,2ZK1,2ZK0,2I4Z,2I4P,2I4J,6ENQ,6AN1,3PO9,3PBA,6KTN,6KTM,8C0C,8ADF,7CXK,7CXL,7CXF,1I7I,3VN2,7CXJ,7CXE,3OSW,3OSI,2ZVT,7E0A,1NYX,8ZFT,8ZFS,8ZFR,8ZFQ,8ZFP,8ZFO,8ZFN,8FHG,8FHF,8FHE,8CPJ,8CPI,8CPH,8ATZ,8ATY,7P4E,7AWD,7AWC,7A7H,6Y3U,6VZO,6VZL,6TSG,6T6B,6PDZ,6ONJ,6ONI,6O68,6O67,6MD4,6MD2,6MD1,6MD0,6MCZ,6FZP,6DGO,4R2U,9O9N,9IWK,9CWN,9CK0,8HUP,8HUM,8FKG,8FKF,8FKE,8FKD,8FKC,8B95,8B94,8B93,8B92,8B90,8B8Y,8B8X,8B8W,8AQN,8AQM,7WGQ,7WGP,7WGO,7RLE,6DGQ,6DGL,6AVI,6AUG,4XLD,3TY0,3BC5,2P4Y,1ZEO,6FZG,8U57,7SQB,7SQA,6IJS,6FZJ,6DGR,6DGP,6DCU,6DBH,6D94,6D8X,3R5N,2XKW,1KNU,9L3T,8SC9,8PBO,8HHQ,8HHP,7WOX,7LOT,7EFQ,6JF0,6JEY,6FZY,6FZF,5WR1,5WR0,5WQX,5AZV,4XUM,4XUH,4XTA,3X1I,3X1H,3SZ1,2VV4,2VV3,2VV2,2VV1,2VV0,2VST,2VSR,2OM9,1WM0,8B91,8B8Z,6T1S,3PRG,3B0R,3B0Q,6T1V,6C1I,4R6S,7AHJ,6E5A,5U5L,5TTO,4R06,2Q6S,2Q6R,2Q61,2Q5S,2Q5P,2Q59,6VZN,6VZM,4OJ4,7JQG,7E2O,6MS7,8WFE,8DK4,6ILQ,6ICJ,5TWO,4CI5,3KMG,3K8S,3H0A,3FUR,2POB,1ZGY,1FM9,1FM6,8DSZ,8DSY,8DKV,8DKN,5JI0,2HFP,1K74,9F7X,9F7W,8BFF,8BF2,8BF1,6IZN,6IZM,5Z6S,5Z5S,4F9M,3V9Y,3V9V,3V9T,3T03,3S9S,3LMP,3B1M,5Y2T,5Y2O,3WJ5,3WJ4,6TDC,6DHA,6DH9,6C5T,5UGM,4EMA,4EM9,3QT0,3NOA,3IA6,3GBK,3G9E,3FEJ,3ET3,3ET0,2Q8S,2PRG,2HWR,2HWQ,2GTK,2G0H",")<Output format>
{{
  ""Mechanism"": ""<Pioglitazone targets peroxisome proliferator-activated receptor gamma (PPARγ) which is involved in cell proliferation, differentiation, and apoptosis. In colorectal cancer, PPARγ plays a role in promoting tumour growth and metastasis."",
  ""Pathways"": ""<PPARγ activation leads to increased expression of genes involved in cell survival, angiogenesis, and metastasis. It also promotes insulin resistance, which can contribute to tumour progression and resistance to therapy."",
  ""Uncertainties"": ""<No clear evidence linking Pioglitazone to colorectal cancer treatment outcomes or mechanisms. However, the involvement of PPARγ in colorectal cancer suggests potential therapeutic targets for future studies>""
}}
</Output format>

The provided PDB IDs (3E00, 3DZY, 3DZU, 7QB1, 6L89, 6K0T, 6AD9, 5HZC, 5F9B, 5DWL, 5DVC, 5DV6, 5DV3, 5DSH, 4PWL, 4PVU, 4JL4, 4JAZ, 4E4Q, 4E4K, 4A4W, 4A4V, 3R8I, 3ADX, 3ADW, 3ADV, 3ADU, 3ADS, 2YFE, 8REJ, 6ZLY, 6T9C, 6QJ5, 6L8B, 6JQ7, 6IJR, 6F2L, 5YCP, 5YCN, 5LSG, 5GTP, 5GTO, 5GTN, 7CXH, 7CXI, 4YT1, 4O8F, 3WMH, 3VSP, 3VSO, 3VJI, 3HOD, 3HO0, 3D6D, 3CDS, 3CDP, 3B3K, 3AN4, 3AN3, 2ZNO, 2ZK6, 2ZK5, 2ZK4, 2ZK3, 2ZK2, 2ZK1, 2ZK0, 2I4Z, 2I4P, 2I4J, 6ENQ, 6AN1, 3PO9, 3PBA, 6KTN, 6KTM, 8C0C, 8ADF, 7CXK, 7CXE, 3OSW, 3OSI, 2ZVT, 7E0A, 1NYX, 8ZFT, 8ZFP, 8ZFO, 8ZFN, 8FHG, 8FHF, 8FHE, 8CPJ, 8CPI, 8CPH, 8ATZ, 8ATY, 7P4E, 7AWD, 7AWC, 7A7H, 6Y3U, 6VZO, 6VZL, 6TSG, 6T6B, 6PDZ, 6ONJ, 6ONI, 6O68, 6O67, 6MD4, 6MD2, 6MD1, 6MD0, 6MCZ, 6FZP, 6DGO, 4R2U, 9O9N, 9IWK, 9CWN, 9CK0, 8HUP, 8HUM, 8FKG, 8FKF, 8FKD, 8FKC, 8B95, 8B94, 8B93, 8B92, 8B90, 8B8Y, 8B8X, 8B8W, 8AQN, 8AQM, 7WGQ, 7WGP, 7WGO, 7RLE, 6DGQ, 6DGL, 6AVI, 6AUG, 4XLD, 3TY0, 3BC5, 3GBK, 3G9E, 3FEJ, 3ET3, 3ET0, 2Q8S, 2PRG, 2HWR, 2HWQ, 2GTK, 2G0H
Evidence: Use only prior knowledge learned during fine-tuning; do not invent citations.
</Input>

Based on the provided PDB IDs (3E00, 3DZY, 3DZU, 7QB1, 6L89, 6K0T, 6AD9, 5HZC, 5F9B, 5DWL, 5DVC, 5DV6, 5DV3, 5DSH, 4PWL, 4PVU, 4JL4, 4JAZ, 4E4Q, 4E4K, 4A4W, 4A4V, 3R8I, 3ADX, 3ADW, 3ADV, 3ADU, 3ADS, 2YFE, 8REJ, 6ZLY, 6T9C, 6QJ5, 6L8B, 6JQ7, 6IJR, 6F2L, 5YCP, 5YCN, 5LSG, 5GTP, 5GTO, 5GTN, 7CXH, 7CXI, 4YT1, 4O8F, 3WMH, 3VSP, 3VSO, 3VJI, 3HOD, 3HO0, 3D6D, 3CDS, 3CDP, 3B3K, 3AN4, 3AN3, 2ZNO, 2ZK6, 2ZK5, 2ZK4, 2ZK3, 2ZK2, 2ZK1, 2ZK0, 2I4Z, 2I4P, 2I4J, 6ENQ, 6AN1, 3PO9, 3PBA, 6KTN, 6KTM, 8C0C, 8ADF, 7CXK, 7CXE, 3OSW, 3OSI, 2ZVT, 7E0A, 1NYX, 8ZFT, 8ZFP, 8ZFO, 8ZFN, 8FHG, 8FHF, 8FHE, 8CPJ, 8CPI, 8CPH, 8ATZ, 8ATY, 7P4E, 7AWD, 7AWC, 7A7H, 6Y3U, 6VZO, 6VZL, 6TSG, 6T6B, 6PDZ, 6ONJ, 6ONI, 6O68, 6O67, 6MD4, 6MD2, 6MD1, 6MD0, 6MCZ, 6FZP, 6DGO, 4R2U, 9O9N, 9IWK, 9CWN, 9CK0, 8HUP, 8HUM, 8FKG, 8FKF, 8FKD, 8FKC, 8B95, 8B94, 8B93, 8B92, 8B90, 8B8Y, 8B8X, 8B8W, 8AQN, 8AQM, 7WGQ, 7WGP, 7WGO, 7RLE, 6DGQ, 6DGL, 6AVI, 6AUG, 4XLD, 3TY0, 3BC5, 3GBK, 3G9E, 3FEJ, 3ET3, 3ET0, 2Q8S, 2PRG, 2HWR, 2HWQ, 2GTK, 2G0H
Evidence: Use only prior knowledge learned during fine-tuning; do not invent citations.
</Input>

Based on the provided PDB IDs (3E00, 3DZY, 3DZU, 7QB1, 6L89, 6K0T, 6AD9, 5HZC, 5F9B, 5DWL, 5DVC, 5DV6, 5DV3, 5DSH, 4PWL, 4PVU, 4JL4, 4JAZ, 4E4Q, 4E4K, 4A4W, 4A4V, 3R8I, 3ADX, 3ADW, 3ADV, 3ADU, 3ADS, 2YFE, 8REJ, 6ZLY, 6T9C, 6QJ5, 6L8B, 6JQ7, 6IJR, 6F2L, 5YCP, 5YCN, 5LSG, 5GTP, 5GTO, 5GTN, 7CXH, 7CXI, 4YT1, 4O8F, 3WMH, 3VSP, 3VSO, 3VJI, 3HOD, 3HO0, 3D6D, 3CDS, 3CDP, 3B3K, 3AN4, 3AN3, 2ZNO, 2ZK6, 2ZK5, 2ZK4, 2ZK3, 2ZK2, 2ZK1, 2ZK0, 2I4Z, 2I4P, 2I4J, 6ENQ, 6AN1, 3PO9, 3PBA, 6KTN, 6KTM, 8C0C, 8ADF, 7CXK, 7CXE, 3OSW, 3OSI, 2ZVT, 7E0A, 1NYX, 8ZFT, 8ZFP, 8ZFO, 8ZFN, 8FHG, 8FHF, 8FHE, 8CPJ, 8CPI, 8CPH, 8ATZ, 8ATY, 7P4E, 7AWD, 7AWC, 7A7H, 6Y3U, 6VZO, 6VZL, 6TSG, 6T6B, 6PDZ, 6ONJ, 6ONI, 6O68, 6O67, 6MD4, 6MD2, 6MD1, 6MD0, 6MCZ, 6FZP, 6DGO, 4R2U, 9O9N, 9IWK, 9CWN, 9CK0, 8HUP, 8HUM, 8FKG, 8FKF, 8FKD, 8FKC, 8B95, 8B94, 8B93, 8B92, 8B90, 8B8Y, 8B8X, 8B8W, 8AQN, 8AQM, 7WGQ, 7WGP, 7WGO, 7RLE, 6DGQ, 6DGL, 6AVI, 6AUG, 4XLD, 3TY0, 3BC5, 3GBK, 3G9E, 3FEJ, 3ET3, 3ET0, 2Q8S, 2PRG, 2HWR, 2HWQ, 2GTK, 2G0H
Evidence: Use only prior knowledge learned during fine-tuning; do not invent citations.
</Input>

Based on the provided PDB IDs (3E00, 3DZY, 3DZU, 7QB1, 6L89, 6K0T, 6AD9, 5HZC, 5F9B, 5DWL, 5DVC, 5DV6, 5DV3, 5DSH, 4PWL, 4PVU, 4JL4, 4JAZ, 4E4Q, 4E4K, 4A4W, 4A4V, 3R8I, 3ADX, 3ADW, 3ADV, 3ADU, 3ADS, 2YFE, 8REJ, 6ZLY, 6T9C, 6QJ5, 6L8B, 6JQ7, 6IJR, 6F2L, 5YCP, 5YCN, 5LSG, 5GTP, 5GTO, 5GTN, 7CXH, 7CXI, 4YT1, 4O8F, 3WMH, 3VSP, 3VSO, 3VJI, 3HOD, 3HO0, 3D6D, 3CDS, 3CDP, 3B3K, 3AN4, 3AN3, 2ZNO, 2ZK6, 2ZK5, 2ZK4, 2ZK3, 2ZK2, 2ZK1, 2ZK0, 2I4Z, 2I4P, 2I4J, 6ENQ, 6AN1, 3PO9, 3PBA, 6KTN, 6KTM, 8C0C, 8ADF, 7CXK, 7CXE, 3OSW, 3OSI, 2ZVT, 7E0A, 1NYX, 8ZFT, 8ZFP, 8ZFO, 8ZFN, 8FHG, 8FHF, 8FHE, 8CPJ, 8CPI, 8CPH, 8ATZ, 8ATY, 7P4E, 7AWD, 7AWC, 7A7H, 6Y3U, 6VZO, 6VZL, 6TSG, 6T6B, 6PDZ, 6ONJ, 6ONI, 6O68, 6O67, 6MD4, 6MD2, 6MD1, 6MD0, 6MCZ, 6FZP, 6DGO, 4R2U, 9O9N, 9IWK, 9CWN, 9CK0, 8HUP, 8HUM, 8FKG, 8FKF, 8FKD, 8FKC, 8B95, 8B94, 8B93, 8B92, 8B90, 8B8Y, 8B8X, 8B8W, 8AQN, 8AQM, 7WGQ, 7WGP, 7WGO, 7RLE, 6DGQ, 6DGL, 6AVI, 6AUG, 4XLD, 3TY0, 3BC5, 3GBK, 3G9E, 3FEJ, 3ET3, 3ET0, 2Q8S, 2PRG, 2HWR, 2HWQ, 2GTK, 2G0H
Evidence: Use only prior knowledge learned during fine-tuning; do not invent citations.
</Input>

Based on the provided PDB IDs (3E00, 3DZY, 3DZU, 7QB1, 6L89, 6K0T, 6AD9, 5HZC, 5F9B, 5DWL, 5DVC, 5DV6, 5DV3, 5DSH, 4PWL, 4PVU, 4JL4, 4JAZ, 4E4Q, 4E4K, 4A4W, 4A4V, 3R8I, 3ADX, 3ADW, 3ADV, 3ADU, 3ADS, 2YFE, 8REJ, 6ZLY, 6T9C, 6QJ5, 6L8B, 6JQ7, 6IJR, 6F2L, 5YCP, 5YCN, 5LSG, 5GTP, 5GTO, 5GTN, 7CXH, 7CXI, 4YT1, 4O8F, 3WMH, 3VSP, 3VSO, 3VJI, 3HOD, 3HO0, 3D6D, 3CDS, 3CDP, 3B3K, 3AN4, 3AN3, 2ZNO, 2ZK6, 2ZK5, 2ZK4, 2ZK3, 2ZK2, 2ZK1, 2ZK0, 2I4Z, 2I4P, 2I4J, 6ENQ, 6AN1, 3PO9, 3PBA, 6KTN, 6KTM, 8C0C, 8ADF, 7CXK, 7CXE, 3OSW, 3OSI, 2ZVT, 7E0A, 1NYX,",basic
Alogliptin,Dipeptidyl peptidase 4,"2QTB,2QT9,2BGR,2JID,3F8S,2QJR,3W2T,3VJM,3VJL,3VJK,1WCY,1J2E,3QBJ,1PFQ,4PV7,8ZDX,2RIP,9JMM,9JMJ,5Y7K,5Y7J,5Y7H,4LKO,4L72,4JH0,4J3J,4DTC,4DSZ,4DSA,3OC0,3KWJ,3KWF,3H0C,3EIO,3BJM,2OQI,2OLE,2OGZ,2BUB,2BGN,2AJL,1W1I,1TKR,1TK3,1RWQ,1NU8,1NU6,1N1M,8WKU,4QZV,3SX4,3SWW,3Q0T,3NOX,2RGU,1R9N,9GOH,5KBY,4KR0,4G1F,3OPM,3O9V,3O95,3G0G,3G0D,3G0C,3G0B,3CCC,3CCB,1U8E,1R9M,3WQH,6B1O,6B1E,5T4H,5T4F,5T4E,5T4B,5ISM,5I7U,4PNZ,4N8E,4N8D,4A5S,3HAC,3HAB,3D4L,3C45,3C43,2QOE,2QKY,2P8S,2OPH,2IIV,2IIT,2HHA,2FJP,1X70,2ONC,5ZID,5J3J,2OQV,2OAG,2I78,2I03,2G63,2G5T,2G5P,3Q8W,9LBT,5LLS,8ZE6,7XNM,2BUC,2BUA,2AJD,2AJC,2AJB,2AJ8,1ORW,1ORV",")<Output format>
{{
  ""Mechanism"": ""<Alogliptin targets Dipeptidyl peptidase 4 (DPP4) in the liver and pancreas, but its role in colorectal cancer is unclear."",
  ""Pathways"": ""<Colorectal cancer signalling involves DPP4, but its involvement in colorectal cancer is not well established."",
  ""Uncertainties"": ""<Uncertainty: The role of Alogliptin in colorectal cancer is unclear, and more research is needed to understand its impact on this disease."",
  ""Other"":
    ""<Evidence: There is limited evidence linking Alogliptin with colorectal cancer, suggesting it may have little to no direct impact on this disease."",
    ""<Evidence: Some studies suggest that Alogliptin may have protective effects against colorectal cancer, but more research is needed to confirm these findings."",
    ""<Evidence: Other studies suggest that Alogliptin may have anti-cancer effects in other contexts, such as pancreatic cancer, but these findings are not directly applicable to colorectal cancer."",
  }
}}
</Output format>

The provided evidence does not support a direct link between Alogliptin and colorectal cancer, nor does it provide clear evidence for its involvement in this disease. Therefore, the relationship between Alogliptin and colorectal cancer remains uncertain.

In summary, the available evidence does not establish a clear mechanism by which Alogliptin might influence colorectal cancer, nor does it provide sufficient evidence to support a direct link between Alogliptin and this disease.",basic
Linagliptin,Dipeptidyl peptidase 4,"2QTB,2QT9,2BGR,2JID,3F8S,2QJR,3W2T,3VJM,3VJL,3VJK,1WCY,1J2E,3QBJ,1PFQ,4PV7,8ZDX,2RIP,9JMM,9JMJ,5Y7K,5Y7J,5Y7H,4LKO,4L72,4JH0,4J3J,4DTC,4DSZ,4DSA,3OC0,3KWJ,3KWF,3H0C,3EIO,3BJM,2OQI,2OLE,2OGZ,2BUB,2BGN,2AJL,1W1I,1TKR,1TK3,1RWQ,1NU8,1NU6,1N1M,8WKU,4QZV,3SX4,3SWW,3Q0T,3NOX,2RGU,1R9N,9GOH,5KBY,4KR0,4G1F,3OPM,3O9V,3O95,3G0G,3G0D,3G0C,3G0B,3CCC,3CCB,1U8E,1R9M,3WQH,6B1O,6B1E,5T4H,5T4F,5T4E,5T4B,5ISM,5I7U,4PNZ,4N8E,4N8D,4A5S,3HAC,3HAB,3D4L,3C45,3C43,2QOE,2QKY,2P8S,2OPH,2IIV,2IIT,2HHA,2FJP,1X70,2ONC,5ZID,5J3J,2OQV,2OAG,2I78,2I03,2G63,2G5T,2G5P,3Q8W,9LBT,5LLS,8ZE6,7XNM,2BUC,2BUA,2AJD,2AJC,2AJB,2AJ8,1ORW,1ORV",")<Output format>
{{
  ""Mechanism"": ""<Linagliptin targets Dipeptidyl peptidase 4 (DPP4) in the liver and colorectal cancer cells."",
  ""Pathways"": ""<DPP4 inhibition of colorectal cancer progression through AMPK activation and AMPK inhibition of mTOR signaling in colorectal cancer cells>"",
  ""Uncertainties"": ""<The exact mechanisms of DPP4 inhibition in colorectal cancer are unclear, but it may involve AMPK activation and AMPK inhibition of mTOR signaling in colorectal cancer cells.>""
}}
</Output format>

The drug Linagliptin targets Dipeptidyl peptidase 4 (DPP4) in the liver and colorectal cancer cells. 
DPP4 inhibition of colorectal cancer progression through AMPK activation and AMPK inhibition of mTOR signaling in colorectal cancer cells. 
Uncertainties include the exact mechanisms of DPP4 inhibition in colorectal cancer and whether it involves AMPK activation and AMPK inhibition of mTOR signaling in colorectal cancer cells.",basic
Sitagliptin,Dipeptidyl peptidase 4,"2QTB,2QT9,2BGR,2JID,3F8S,2QJR,3W2T,3VJM,3VJL,3VJK,1WCY,1J2E,3QBJ,1PFQ,4PV7,8ZDX,2RIP,9JMM,9JMJ,5Y7K,5Y7J,5Y7H,4LKO,4L72,4JH0,4J3J,4DTC,4DSZ,4DSA,3OC0,3KWJ,3KWF,3H0C,3EIO,3BJM,2OQI,2OLE,2OGZ,2BUB,2BGN,2AJL,1W1I,1TKR,1TK3,1RWQ,1NU8,1NU6,1N1M,8WKU,4QZV,3SX4,3SWW,3Q0T,3NOX,2RGU,1R9N,9GOH,5KBY,4KR0,4G1F,3OPM,3O9V,3O95,3G0G,3G0D,3G0C,3G0B,3CCC,3CCB,1U8E,1R9M,3WQH,6B1O,6B1E,5T4H,5T4F,5T4E,5T4B,5ISM,5I7U,4PNZ,4N8E,4N8D,4A5S,3HAC,3HAB,3D4L,3C45,3C43,2QOE,2QKY,2P8S,2OPH,2IIV,2IIT,2HHA,2FJP,1X70,2ONC,5ZID,5J3J,2OQV,2OAG,2I78,2I03,2G63,2G5T,2G5P,3Q8W,9LBT,5LLS,8ZE6,7XNM,2BUC,2BUA,2AJD,2AJC,2AJB,2AJ8,1ORW,1ORV",")<Output format>
{{
  ""Mechanism"": ""<Sitagliptin acts as a DPP-4 inhibitor, which increases glucose levels in the blood by reducing hepatic glucose production and increasing insulin secretion. This action is believed to contribute to improved glycemic control in patients with type 2 diabetes."",
  ""Pathways"": ""<The drug's action on DPP-4 inhibits the enzyme dipeptidyl peptidase-4, which breaks down incretin hormones such as GLP-1 and GLP-5. These hormones enhance insulin secretion, inhibit glucagon release, and decrease hepatic glucose production. By increasing GLP-1 and GLP-5 levels, GLP-1 stimulates the release of insulin from pancreatic beta cells, and GLP-5 enhances insulin secretion from the pancreas. GLP-1 also reduces glucagon release from the pancreas and decreases hepatic glucose production."",
  ""Uncertainties"": ""<Sitagliptin's exact mechanism of action is still being studied. However, it is known that it improves glycemic control in patients with type 2 diabetes, and this improvement is likely due to its effects on incretin hormones and insulin secretion. The exact molecular interactions between sitagliptin and DPP-4 are not well understood, but it is thought to involve the inhibition of DPP-4, leading to increased levels of incretin hormones. However, more research is needed to fully understand sitagliptin's molecular interactions and its role in colorectal cancer."",
  ""Uncertainties"": ""<Further research is needed to understand the molecular interactions between sitagliptin and colorectal cancer. It is also unclear how sitagliptin affects colorectal cancer, although there is evidence that it may have anti-cancer effects. More studies are needed to clarify these points."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Mechanism"": ""<Sitagliptin's action on DPP-4 inhibits the enzyme dipeptidyl peptidase-4, which breaks down incretin hormones such as GLP-1 and GLP-5. These hormones enhance insulin secretion, inhibit glucagon release, and decrease hepatic glucose production. By increasing GLP-1 and GLP-5 levels, GLP-1 stimulates the release of insulin from pancreatic beta cells, and GLP-5 enhances insulin secretion from the pancreas. GLP-1 also reduces glucagon release from the pancreas and decreases hepatic glucose production."",
  ""Pathways"": ""<Sitagliptin's action on DPP-4 inhibits the enzyme dipeptidyl peptidase-4, which breaks down incretin hormones such as GLP-1 and GLP-5. These hormones enhance insulin secretion, inhibit glucagon release, and decrease hepatic glucose production. By increasing GLP-1 and GLP-5 levels, GLP-1 stimulates the release of insulin from pancreatic beta cells, and GLP-5 enhances insulin secretion from the pancreas. GLP-1 also reduces glucagon release from the pancreas and decreases hepatic glucose production."",
  ""Uncertainties"": ""<Sitagliptin's exact mechanism of action is still being studied. However, it is known that it improves glycemic control in patients with type 2 diabetes, and this improvement is likely due to its effects on incretin hormones and insulin secretion. The exact molecular interactions between sitagliptin and DPP-4 are not well understood, but it is thought to involve the inhibition of DPP-4, leading to increased levels of incretin hormones. However, more research is needed to fully understand sitagliptin's molecular interactions and its role in colorectal cancer."",
  ""Uncertainties"": ""<Further research is needed to understand the molecular interactions between sitagliptin and colorectal cancer. It is also unclear how sitagliptin affects colorectal cancer, although there is evidence that it may have anti-cancer effects. More studies are needed to clarify these points."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Mechanism"": ""<Sitagliptin's action on DPP-4 inhibits the enzyme dipeptidyl peptidase-4, which breaks down incretin hormones such as GLP-1 and GLP-5. These hormones enhance insulin secretion, inhibit glucagon release, and decrease hepatic glucose production. By increasing GLP-1 and GLP-5 levels, GLP-1 stimulates the release of insulin from pancreatic beta cells, and GLP-5 enhances insulin secretion from the pancreas. GLP-1 also reduces glucagon release from the pancreas and decreases hepatic glucose production."",
  ""Pathways"": ""<Sitagliptin's action on DPP-4 inhibits the enzyme dipeptidyl peptidase-4, which breaks down incretin hormones such as GLP-1 and GLP-5. These hormones enhance insulin secretion, inhibit glucagon release, and decrease hepatic glucose production. By increasing GLP-1 and GLP-5 levels, GLP-1 stimulates the release of insulin from pancreatic beta cells, and GLP-5 enhances insulin secretion from the pancreas. GLP-1 also reduces glucagon release from the pancreas and decreases hepatic glucose production."",
  ""Uncertainties"": ""<Sitagliptin's exact mechanism of action is still being studied. However, it is known that it improves glycemic control in patients with type 2 diabetes, and this improvement is likely due to its effects on incretin hormones and insulin secretion. The exact molecular interactions between sitagliptin and DPP-4 are not well understood, but it is thought to involve the inhibition of DPP-4, leading to increased levels of incretin hormones. However, more research is needed to fully understand sitagliptin's molecular interactions and its role in colorectal cancer."",
  ""Uncertainties"": ""<Further research is needed to understand the molecular interactions between sitagliptin and colorectal cancer. It is also unclear how sitagliptin affects colorectal cancer, although there is evidence that it may have anti-cancer effects. More studies are needed to clarify these points."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Mechanism"": ""<Sitagliptin's action on DPP-4 inhibits the enzyme dipeptidyl peptidase-4, which breaks down incretin hormones such as GLP-1 and GLP-5. These hormones enhance insulin secretion, inhibit glucagon release, and decrease hepatic glucose production. By increasing GLP-1 and GLP-5 levels, GLP-1 stimulates the release of insulin from pancreatic beta cells, and GLP-5 enhances insulin secretion from the pancreas. GLP-1 also reduces glucagon release from the pancreas and decreases hepatic glucose production."",
  ""Pathways"": ""<Sitagliptin's action on DPP-4 inhibits the enzyme dipeptidyl peptidase-4, which breaks down incretin hormones such as GLP-1 and GLP-5. These hormones enhance insulin secretion, inhibit glucagon release, and decrease hepatic glucose production. By increasing GLP-1 and GLP-5 levels, GLP-1 stimulates the release of insulin from pancreatic beta cells, and GLP-5 enhances insulin secretion from the pancreas. GLP-1 also reduces glucagon release from the pancreas and decreases hepatic glucose production."",
  ""Uncertainties"": ""<Sitagliptin's exact mechanism of action is still being studied. However, it is known that it improves glycemic control in patients with type 2 diabetes, and this improvement is likely due to its effects on incretin hormones and insulin secretion. The exact molecular interactions between sitagliptin and DPP-4 are not well understood, but it is thought to involve the inhibition of DPP-4, leading to increased levels of incretin hormones. However, more research is needed to fully understand sitagliptin's molecular interactions and its role in colorectal cancer."",
  ""Uncertainties"": ""<Further research is needed to understand the molecular interactions between sitagliptin and colorectal cancer. It is also unclear how sitagliptin affects colorectal cancer, although there is evidence that it may have anti-cancer effects. More studies are needed to clarify these points."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Mechanism"": ""<Sitagliptin's action on DPP-4 inhibits the enzyme dipeptidyl peptidase-4, which breaks down incretin hormones such as GLP-1 and GLP-5. These hormones enhance insulin secretion, inhibit glucagon release, and decrease hepatic glucose production. By increasing GLP-1 and GLP-5 levels, GLP-1 stimulates the release of insulin from pancreatic beta cells, and GLP-5 enhances insulin secretion from the pancreas. GLP-1 also reduces glucagon release from the pancreas and decreases hepatic glucose production."",
  ""Pathways"": ""<Sitagliptin's action on DPP-4 inhibits the enzyme dipeptidyl peptidase-4, which breaks down incretin hormones such as GLP-1 and GLP-5. These hormones enhance insulin secretion, inhibit glucagon release, and decrease hepatic glucose production. By increasing GLP-1 and GLP-5 levels, GLP-1 stimulates the release of insulin from pancreatic beta cells, and GLP-5 enhances insulin secretion from the pancreas. GLP-1 also reduces glucagon release from the pancreas and decreases hepatic glucose production."",
  ""Uncertainties"": ""<Sitagliptin's exact mechanism of action is still being studied. However, it is known that it improves glycemic control in patients with type 2 diabetes, and this improvement is likely due to its effects on incretin hormones and insulin secretion. The exact molecular interactions between sitagliptin and DPP-4 are not well understood, but it is thought to involve the inhibition of DPP-4, leading to increased levels of incretin hormones. However, more research is needed to fully understand sitagliptin's molecular interactions and its role in colorectal cancer."",
  ""Uncertainties"": ""<Further research is needed to understand the molecular interactions between sitagliptin and colorectal cancer. It is also unclear how sitagliptin affects colorectal cancer, although there is evidence that it may have anti-cancer effects. More studies are needed to clarify these points."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Mechanism"": ""<Sitagliptin's action on DPP-4 inhibits the enzyme dipeptidyl peptidase-4, which breaks down incretin hormones such as GLP-1 and GLP-5. These hormones enhance insulin secretion, inhibit glucagon release, and decrease hepatic glucose production. By increasing GLP-1 and GLP-5 levels, GLP-1 stimulates the release of insulin from pancreatic beta cells, and GLP-5 enhances insulin secretion from the pancreas. GLP-1 also reduces glucagon release from the pancreas and decreases hepatic glucose production."",
  ""Pathways"": ""<Sitagliptin's action on DPP-4 inhibits the enzyme dipeptidyl peptidase-4, which breaks down incretin hormones such as GLP-1 and GLP-5. These hormones enhance insulin secretion, inhibit glucagon release, and decrease hepatic glucose production. By increasing GLP-1 and GLP-5 levels, GLP-1 stimulates the release of insulin from pancreatic beta cells, and GLP-5 enhances insulin secretion from the pancreas. GLP-1 also reduces glucagon release from the pancreas and decreases hepatic glucose production."",
  ""Uncertainties"": ""<Sitagliptin's exact mechanism of action is still being studied. However, it is known that it improves glycemic control in patients with type 2 diabetes, and this improvement is likely due to its effects on incretin hormones and insulin secretion. The exact molecular interactions between sitagliptin and DPP-4 are not well understood, but it is thought to involve the inhibition of DPP-4, leading to increased levels of incretin hormones. However, more research is needed to fully understand sitagliptin's molecular interactions and its role in colorectal cancer."",
  ""Uncertainties"": ""<Further research is needed to understand the molecular interactions between sitagliptin and colorectal cancer. It is also unclear how sitagliptin affects colorectal cancer, although there is evidence that it may have anti-cancer effects. More studies are needed to clarify these points."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Mechanism"": ""<Sitagliptin's action on DPP-4 inhibits the enzyme dipeptidyl peptidase-4, which breaks down incretin hormones such as GLP-1 and GLP-5. These hormones enhance insulin secretion, inhibit glucagon release, and decrease hepatic glucose production. By increasing GLP-1 and GLP-5 levels, GLP-1 stimulates the release of insulin from pancreatic beta cells, and GLP-5 enhances insulin secretion from the pancreas. GLP-1 also reduces glucagon release from the pancreas and decreases hepatic glucose production."",
  ""Pathways"": ""<Sitagliptin's action on DPP-4 inhibits the enzyme dipeptidyl peptidase-4, which breaks down incretin hormones such as GLP-1 and GLP-5. These hormones enhance insulin secretion, inhibit glucagon release, and decrease hepatic glucose production. By increasing GLP-1 and GLP-5 levels, GLP-1 stimulates the release of insulin from pancreatic beta cells, and GLP-5 enhances insulin secretion from the pancreas. GLP-1 also reduces glucagon release from the pancreas and decreases hepatic glucose production."",
  ""Uncertainties"": ""<Sitagliptin's exact mechanism of action is still being studied. However, it is known that it improves glycemic control in patients with type 2 diabetes, and this improvement is likely due to its effects on incretin hormones and insulin secretion. The exact molecular interactions between sitagliptin and DPP-4 are not well understood, but it is thought to involve the inhibition of DPP-4, leading to increased levels of incretin hormones. However, more research is needed to fully understand sitagliptin's molecular interactions and its role in colorectal cancer."",
  ""Uncertainties"": ""<Further research is needed to understand the molecular interactions between sitagliptin and colorectal cancer. It is also unclear how sitagliptin affects colorectal cancer, although there is evidence that it may have anti-cancer effects. More studies are needed to clarify these points."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Uncertainties"": ""<More research is needed to understand sitagliptin's molecular interactions with colorectal cancer. There is evidence that it may have anti-cancer effects, but more studies are needed to clarify these findings."",
  ""Mechanism"": ""<Sitagliptin's action on DPP-4 inhibits the enzyme dipeptidyl peptidase-4, which breaks down incretin hormones such as GLP-1 and GLP-5. These hormones enhance insulin secretion, inhibit glucagon release, and decrease hepatic glucose production. By increasing GLP-1 and GL",basic
Saxagliptin,Dipeptidyl peptidase 4,"2QTB,2QT9,2BGR,2JID,3F8S,2QJR,3W2T,3VJM,3VJL,3VJK,1WCY,1J2E,3QBJ,1PFQ,4PV7,8ZDX,2RIP,9JMM,9JMJ,5Y7K,5Y7J,5Y7H,4LKO,4L72,4JH0,4J3J,4DTC,4DSZ,4DSA,3OC0,3KWJ,3KWF,3H0C,3EIO,3BJM,2OQI,2OLE,2OGZ,2BUB,2BGN,2AJL,1W1I,1TKR,1TK3,1RWQ,1NU8,1NU6,1N1M,8WKU,4QZV,3SX4,3SWW,3Q0T,3NOX,2RGU,1R9N,9GOH,5KBY,4KR0,4G1F,3OPM,3O9V,3O95,3G0G,3G0D,3G0C,3G0B,3CCC,3CCB,1U8E,1R9M,3WQH,6B1O,6B1E,5T4H,5T4F,5T4E,5T4B,5ISM,5I7U,4PNZ,4N8E,4N8D,4A5S,3HAC,3HAB,3D4L,3C45,3C43,2QOE,2QKY,2P8S,2OPH,2IIV,2IIT,2HHA,2FJP,1X70,2ONC,5ZID,5J3J,2OQV,2OAG,2I78,2I03,2G63,2G5T,2G5P,3Q8W,9LBT,5LLS,8ZE6,7XNM,2BUC,2BUA,2AJD,2AJC,2AJB,2AJ8,1ORW,1ORV",")<Output format>
{{
  ""Mechanism"": ""<Saxagliptin acts by inhibiting DPP-4, a key enzyme in glucose metabolism and insulin signaling."",
  ""Pathways"": ""<Inhibition of DPP-4 leads to decreased glucagon-like peptide-1 (GLP-1) and increased incretin hormones, which in turn enhance insulin secretion and decrease glucagon levels, leading to decreased hepatic glucose production and improved glycemic control."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have effects on other pathways, such as the PI3K/AKT/mTOR pathway, but these are not directly related to colorectal cancer."",
  ""Uncertainties"": ""<No clear evidence linking saxagliptin to colorectal cancer; however, GLP-1 has been linked to colorectal cancer in some studies."",
  ""Other considerations"": ""<Saxagliptin may also have",basic
Vildagliptin,Dipeptidyl peptidase 4,"2QTB,2QT9,2BGR,2JID,3F8S,2QJR,3W2T,3VJM,3VJL,3VJK,1WCY,1J2E,3QBJ,1PFQ,4PV7,8ZDX,2RIP,9JMM,9JMJ,5Y7K,5Y7J,5Y7H,4LKO,4L72,4JH0,4J3J,4DTC,4DSZ,4DSA,3OC0,3KWJ,3KWF,3H0C,3EIO,3BJM,2OQI,2OLE,2OGZ,2BUB,2BGN,2AJL,1W1I,1TKR,1TK3,1RWQ,1NU8,1NU6,1N1M,8WKU,4QZV,3SX4,3SWW,3Q0T,3NOX,2RGU,1R9N,9GOH,5KBY,4KR0,4G1F,3OPM,3O9V,3O95,3G0G,3G0D,3G0C,3G0B,3CCC,3CCB,1U8E,1R9M,3WQH,6B1O,6B1E,5T4H,5T4F,5T4E,5T4B,5ISM,5I7U,4PNZ,4N8E,4N8D,4A5S,3HAC,3HAB,3D4L,3C45,3C43,2QOE,2QKY,2P8S,2OPH,2IIV,2IIT,2HHA,2FJP,1X70,2ONC,5ZID,5J3J,2OQV,2OAG,2I78,2I03,2G63,2G5T,2G5P,3Q8W,9LBT,5LLS,8ZE6,7XNM,2BUC,2BUA,2AJD,2AJC,2AJB,2AJ8,1ORW,1ORV",")<Output format>
{{
  ""Mechanism"": ""<Vildagliptin targets Dipeptidyl peptidase 4 (DPP4) in the liver and colorectal cancer cells."",
  ""Pathways"": ""<DPP4 inhibition of colorectal cancer progression through AMPK activation and AMPK inhibition of mTOR."",
  ""Uncertainties"": ""<The evidence does not support a role for Vildagliptin in treating colorectal cancer; however, it may have some indirect effects on colorectal cancer risk through metabolic changes or other mechanisms not detailed here>.""
}}
</Output format>

The provided evidence suggests that Vildagliptin targets Dipeptidyl peptidase 4 (DPP4) in the liver and colorectal cancer cells. Specifically, it inhibits DPP4, which is involved in the regulation of glucose metabolism and insulin signaling. Inhibition of DPP4 has been linked to improved outcomes in patients with type 2 diabetes and non-alcoholic fatty liver disease, suggesting potential benefits for colorectal cancer patients.

However, the evidence does not support a direct role for Vildagliptin in treating colorectal cancer; instead, it may have some indirect effects on colorectal cancer risk through metabolic changes or other mechanisms not detailed here.

Uncertainties remain regarding the potential benefits of Vildagliptin in colorectal cancer treatment, particularly given the lack of clear evidence supporting its use in this area. Further research is needed to fully understand the role of Vildagliptin in colorectal cancer care.",basic
Bromocriptine,Dopamine D2 receptor,"8IRS,7JVR,8U02,8TZQ,6VMS","{""Mechanism"": ""<Bromocriptine acts as a dopamine agonist, which may influence cell growth and survival in colorectal cancer cells by modulating the dopaminergic signaling pathway.>"", 
 ""Pathways"": ""<The dopaminergic signaling pathway may contribute to colorectal cancer progression through the PI3K/AKT/mTOR signaling cascade, which is implicated in colorectal tumorigenesis.>"",
 ""Uncertainties"": ""<There are no clear or conflicting mechanisms related to colorectal cancer treatment with bromocriptine.>""}

{""Mechanism"": ""<Bromocriptine may inhibit colorectal cancer cell proliferation and induce apoptosis through the inhibition of mTOR signaling, which is involved in cell growth and survival.>"",
 ""Pathways"": ""<The mTOR pathway is implicated in colorectal tumorigenesis, suggesting that bromocriptine may exert its anti-cancer effects through this pathway.>"",
 ""Uncertainties"": ""<There are no clear or conflicting mechanisms related to colorectal cancer treatment with bromocriptine.>""}

{""Mechanism"": ""<Bromocriptine may influence colorectal cancer cell growth and survival by modulating the PI3K/AKT/mTOR signaling cascade, which is implicated in colorectal tumorigenesis.>"",
 ""Pathways"": ""<The PI3K/AKT/mTOR signaling cascade is involved in colorectal cancer progression, suggesting that bromocriptine may exert its anti-cancer effects through this pathway.>"",
 ""Uncertainties"": ""<There are no clear or conflicting mechanisms related to colorectal cancer treatment with bromocriptine.>}

<Output>
{{
  ""Mechanism"": ""<Bromocriptine's action on the dopaminergic signaling pathway may influence colorectal cancer cell growth and survival."",
  ""Pathways"": ""<The dopaminergic signaling pathway may contribute to colorectal cancer progression through the PI3K/AKT/mTOR signaling cascade."",
  ""Uncertainties"": ""<There are no clear or conflicting mechanisms related to colorectal cancer treatment with bromocriptine.>""
}}
</Output>

print(""NO RELATION"")
print(""Bromocriptine may influence colorectal cancer cell growth and survival through modulation of the PI3K/AKT/mTOR signaling cascade."")

print(""<Bromocriptine may influence colorectal cancer cell growth and survival through modulation of the PI3K/AKT/mTOR signaling cascade.,>"")

print(""Bromocriptine may influence colorectal cancer cell growth and survival through modulation of the PI3K/AKT/mTOR signaling cascade."")",basic
Canagliflozin,Sodium/glucose cotransporter 2,"7YNK,7YNJ,7VSI,8HIN,8HG7,8HEZ,8HDH,8HB0","""<Canagliflozin targets sodium/glucose cotransporter 2, and evidence suggests it inhibits this transporter. This inhibition can lead to increased glucose levels in the bloodstream, which may promote colorectal cancer growth. However, the exact mechanisms by which Canagliflozin affects colorectal cancer are unclear. Further research is needed to fully understand its role in this disease.""

{""Mechanism"": ""<Inhibition of sodium/glucose cotransporter 2 by Canagliflozin may contribute to colorectal cancer progression by altering metabolic and hormonal signals.>""
{""Pathways"": ""<Glucose metabolism alterations may contribute to colorectal cancer through insulin/IGF-1 signaling dysregulation, epigenetic changes, and altered gut microbiota.>""
{""Uncertainties"": ""<The direct link between Canagliflozin and colorectal cancer is unclear. Further research is necessary to establish a mechanistic connection.>""}

<Output>
The provided evidence supports that Canagliflozin inhibits sodium/glucose cotransporter 2, leading to increased glucose levels in the bloodstream, which may promote colorectal cancer growth. However, the exact mechanisms by which Canagliflozin affects colorectal cancer are unclear.

<Uncertainties> ""<The direct link between Canagliflozin and colorectal cancer is unclear. Further research is necessary to establish a mechanistic connection.>""
</Uncertainties>

<Summary>
Based on available evidence, Canagliflozin's action on sodium/glucose cotransporter 2 likely contributes to colorectal cancer progression by altering metabolic and hormonal signals. However, the precise mechanisms by which Canagliflozin influences colorectal cancer are still unclear.

</Summary>",basic
Dapagliflozin,Sodium/glucose cotransporter 2,"7YNK,7YNJ,7VSI,8HIN,8HG7,8HEZ,8HDH,8HB0",")<Output format>
 {{
  ""Mechanism"": ""<Dapagliflozin acts as a sodium-glucose cotransporter 2 inhibitor, which increases glucose levels in the bloodstream by reducing glucose reabsorption in the kidneys. This can lead to increased insulin levels and insulin resistance, potentially contributing to colorectal cancer development."",
  ""Pathways"": ""<Insulin signaling pathway activation may contribute to colorectal cancer through insulin resistance, metabolic changes, and potential oncogenic effects."",
  ""Uncertainties"": ""<No clear evidence linking dapagliflozin directly to colorectal cancer prevention or treatment outcomes. However, the potential metabolic and insulin-related pathways suggest a plausible mechanistic link.>""
 }}
</Output format>

<Input>
Drug: Dapagliflozin
Receptor: Sodium/glucose cotransporter 2
PDB IDs (if any): 7YNK,7YNJ,7VSI,8HIN,8HG7,8HEZ,8HDH,8HB0
Evidence: Use only prior knowledge learned during fine-tuning; do not invent citations.
</Input>

Constraints:
- If unclear, explicitly state the uncertainty.
- Consider the broader context of colorectal cancer and known mechanisms of action for similar drugs.
- Be cautious of potential confounding relationships between metabolic changes and cancer risk.
- Note that the provided evidence does not establish a direct causal relationship between dapagliflozin and colorectal cancer.",basic
Empagliflozin,Sodium/glucose cotransporter 2,"7YNK,7YNJ,7VSI,8HIN,8HG7,8HEZ,8HDH,8HB0",")<Output format>
 {{
  ""Mechanism"": ""<Empagliflozin acts as an SGLT inhibitor, blocking the sodium-glucose cotransporter 2 in the kidneys and intestines. This inhibition reduces glucose reabsorption and increases insulin secretion, leading to improved glycemic control. Additionally, empagliflozin has been shown to exert anti-inflammatory and anti-fibrotic effects, which may contribute to its protective effects against cardiovascular disease and kidney disease."",
  ""Pathways"": ""<The anti-diabetic effects of empagliflozin are mediated through its impact on insulin signaling, including the activation of AMP-activated protein kinase (AMPK) and the inhibition of mTOR signaling. These effects contribute to improved glycemic control. In terms of inflammation, empagliflozin has been shown to reduce tumor necrosis factor-alpha (TNF-alpha) levels and increase the expression of anti-inflammatory cytokines such as IL-10 and IL-1RA. Furthermore, empagliflozin may exert protective effects against cardiovascular disease by reducing inflammation and improving endothelial function."",
  ""Uncertainties"": ""<The exact mechanisms by which empagliflozin exerts its protective effects against colorectal cancer are unclear. However, it is hypothesized that empagliflozin may inhibit the growth of colorectal cancer cells through the inhibition of Wnt signaling, which is involved in colorectal tumorigenesis. Moreover, empagliflozin may exert protective effects against colorectal cancer through the modulation of the gut microbiota, which plays a critical role in the development and progression of colorectal cancer. However, the precise mechanisms by which empagliflozin exerts these protective effects are still unclear and require further investigation."",
 }}
</Output format>

<Input>
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug: 
Drug:",basic
Semaglutide,Glucagon-like peptide 1 receptor,"7FIM,7RTB,9J1P,9IVM,9IVG,9EBQ,9EBO,9EBN,9C0K,9BYO,8YWF,8YW3,8WG7,8JIR,8JIP,7VBI,7VBH,7S3I,7S1M,7LLY,7LLL,7LCK,7LCJ,7LCI,7KI1,7KI0,7EVM,7E14,7DUR,7DUQ,7C2E,6X1A,6X19,6X18,6ORV,6B3J,7X8S,7X8R,7RGP,7RG9,6XOX,6VCB,5NX2,8JIS,7S15,6LN2,5VAI,6KK7,6KK1,6KJV,5VEX,5VEW,6GB1,5E94,3IOL,4ZGM,3C5T,3C59,5OTX,5OTW,5OTV,5OTU,5OTT","{""Mechanism"": ""<Semaglutide targets the glucagon-like peptide 1 receptor (GLP1R) in the pancreas, which is involved in glucose metabolism and insulin secretion. GLP1R is also implicated in the regulation of energy homeostasis and body weight. In colorectal cancer, GLP1R signaling has been linked to increased proliferation and survival of colorectal cancer cells. This suggests that semaglutide may have potential anti-cancer effects in colorectal cancer."",
 ""Pathways"": ""<The GLP1R signaling pathway is involved in various physiological processes, including glucose metabolism, insulin secretion, and energy homeostasis. In colorectal cancer, dysregulation of this pathway has been observed, leading to increased cell proliferation and survival. The involvement of GLP1R signaling in colorectal cancer suggests that targeting this pathway may be a viable therapeutic strategy."",
 ""Uncertainties"": ""<No clear evidence links semaglutide to the treatment of colorectal cancer. However, the involvement of GLP1R signaling in colorectal cancer suggests that semaglutide may have potential anti-cancer effects in this disease. Further research is needed to confirm these findings and establish the efficacy of semaglutide in treating colorectal cancer.""}

{""Mechanism"": ""<Semaglutide's action on GLP1R is believed to contribute to its anti-cancer effects in colorectal cancer. By activating GLP1R, semaglutide may inhibit the growth and survival of colorectal cancer cells, leading to reduced tumor size and improved patient outcomes. However, the exact molecular mechanisms underlying semaglutide's anti-cancer effects in colorectal cancer are not fully understood."",
 ""Pathways"": ""<The GLP1R signaling pathway is involved in various physiological processes, including glucose metabolism, insulin secretion, and energy homeostasis. In colorectal cancer, dysregulation of this pathway has been observed, leading to increased cell proliferation and survival. The involvement of GLP1R signaling in colorectal cancer suggests that semaglutide may have potential anti-cancer effects in this disease."",
 ""Uncertainties"": ""<While semaglutide's action on GLP1R is thought to contribute to its anti-cancer effects in colorectal cancer, the exact molecular mechanisms underlying these effects are not fully understood. Further research is needed to confirm these findings and establish the efficacy of semaglutide in treating colorectal cancer.""}

NO RELATION",basic
Exenatide,Glucagon-like peptide 1 receptor,"7FIM,7RTB,9J1P,9IVM,9IVG,9EBQ,9EBO,9EBN,9C0K,9BYO,8YWF,8YW3,8WG7,8JIR,8JIP,7VBI,7VBH,7S3I,7S1M,7LLY,7LLL,7LCK,7LCJ,7LCI,7KI1,7KI0,7EVM,7E14,7DUR,7DUQ,7C2E,6X1A,6X19,6X18,6ORV,6B3J,7X8S,7X8R,7RGP,7RG9,6XOX,6VCB,5NX2,8JIS,7S15,6LN2,5VAI,6KK7,6KK1,6KJV,5VEX,5VEW,6GB1,5E94,3IOL,4ZGM,3C5T,3C59,5OTX,5OTW,5OTV,5OTU,5OTT","{""Mechanism"": ""<Exenatide acts by inhibiting the translocation of glucagon-like peptide 1 (GLP-1) from the nucleus to the cytoplasm, thereby reducing insulin secretion and increasing insulin sensitivity. This action reduces glucose levels and improves glycemic control, which may help reduce the risk of colorectal cancer.>"", 
{""Pathways"": ""<Exenatide's action on GLP-1 receptor is thought to contribute to its anti-cancer effects in colorectal cancer. GLP-1 has been shown to have tumor-suppressive effects in various cancers, including colorectal cancer.>"", 
{""Uncertainties"": ""<Exenatide's exact mechanisms in colorectal cancer are unclear. However, it is believed to exert its anti-cancer effects through multiple pathways, including the inhibition of insulin signaling, reduction of inflammation, and induction of apoptosis in cancer cells.>""}
</Output>

(Note: Based on the provided evidence, it appears that exenatide may have a potential role in reducing the risk of colorectal cancer by improving glycemic control and possibly exerting anti-cancer effects through multiple pathways.)

NO RELATION",basic
Liraglutide,Glucagon-like peptide 1 receptor,"7FIM,7RTB,9J1P,9IVM,9IVG,9EBQ,9EBO,9EBN,9C0K,9BYO,8YWF,8YW3,8WG7,8JIR,8JIP,7VBI,7VBH,7S3I,7S1M,7LLY,7LLL,7LCK,7LCJ,7LCI,7KI1,7KI0,7EVM,7E14,7DUR,7DUQ,7C2E,6X1A,6X19,6X18,6ORV,6B3J,7X8S,7X8R,7RGP,7RG9,6XOX,6VCB,5NX2,8JIS,7S15,6LN2,5VAI,6KK7,6KK1,6KJV,5VEX,5VEW,6GB1,5E94,3IOL,4ZGM,3C5T,3C59,5OTX,5OTW,5OTV,5OTU,5OTT","{""Mechanism"": ""Liraglutide acts by inhibiting glucagon-like peptide-1 (GLP-1) secretion from the pancreatic beta cells."", 
 ""Pathways"": ""Liraglutide has been shown to inhibit the growth of colorectal cancer cells through several signaling pathways, including the PI3K/AKT/mTOR pathway, the MAPK pathway, and the NF-κB pathway."", 
 ""Uncertainties"": ""The exact mechanisms by which liraglutide exerts its effects in colorectal cancer are not fully understood, but it is thought to affect cell proliferation, survival, and angiogenesis.""}
{""Mechanism"": ""Liraglutide acts by binding to GLP-1 receptors in the pancreas."", 
 ""Pathways"": ""Liraglutide's action on GLP-1 receptors may inhibit the growth of colorectal cancer cells through various signaling pathways, including the PI3K/AKT/mTOR pathway, the MAPK pathway, and the NF-κB pathway."", 
 ""Uncertainties"": ""Further research is needed to elucidate the precise molecular mechanisms by which liraglutide exerts its effects in colorectal cancer, including the potential involvement of other signaling pathways and the role of GLP-1 in colorectal cancer progression.""}
</Input>

Constraints:
- If unclear, explicitly state the uncertainty.
- Consider the following potential mechanisms by which liraglutide might exert its effects in colorectal cancer:
    - Inhibition of GLP-1 signaling, which may contribute to reduced tumor growth and metastasis.
    - Modulation of the PI3K/AKT/mTOR pathway, which may affect cell proliferation, survival, and apoptosis.
    - Modulation of the MAPK pathway, which may influence cell proliferation, survival, and angiogenesis.
    - Modulation of the NF-κB pathway, which may impact tumor cell proliferation, survival, and immune responses.
- Consider the potential role of GLP-1 in colorectal cancer progression and the potential mechanisms by which liraglutide might interact with this pathway.
- Evaluate the current evidence for liraglutide's effects on colorectal cancer and consider any emerging findings that may provide further insights into its mechanisms of action.",basic
Albiglutide,Glucagon-like peptide 1 receptor,"7FIM,7RTB,9J1P,9IVM,9IVG,9EBQ,9EBO,9EBN,9C0K,9BYO,8YWF,8YW3,8WG7,8JIR,8JIP,7VBI,7VBH,7S3I,7S1M,7LLY,7LLL,7LCK,7LCJ,7LCI,7KI1,7KI0,7EVM,7E14,7DUR,7DUQ,7C2E,6X1A,6X19,6X18,6ORV,6B3J,7X8S,7X8R,7RGP,7RG9,6XOX,6VCB,5NX2,8JIS,7S15,6LN2,5VAI,6KK7,6KK1,6KJV,5VEX,5VEW,6GB1,5E94,3IOL,4ZGM,3C5T,3C59,5OTX,5OTW,5OTV,5OTU,5OTT","{""Mechanism"": ""<Albiglutide targets GLP1 receptors, which are involved in glucose metabolism and insulin signaling. In colorectal cancer, GLP1 receptors may play a role in promoting cell proliferation and inhibiting apoptosis, contributing to tumour growth and progression.>"",
 ""Pathways"": ""<The GLP1 receptor pathway is implicated in colorectal cancer. GLP1 receptor signaling can lead to increased cell proliferation and survival in the colon, contributing to tumour growth and resistance to chemotherapy. Additionally, GLP1 receptor signaling may promote angiogenesis and metastasis in colorectal cancer.>"",
 ""Uncertainties"": ""<Unclear whether GLP1 receptor signaling directly promotes colorectal cancer. However, GLP1 receptor signaling may contribute to tumour growth and progression through other mechanisms, such as promoting cell proliferation and inhibiting apoptosis.>""

{""Mechanism"": ""<Albiglutide may inhibit GLP1 receptor signaling, potentially reducing colorectal cancer progression. However, the direct relationship between ALG and colorectal cancer is unclear.>"",
 ""Pathways"": ""<Inhibition of GLP1 receptor signaling by ALG may have implications for colorectal cancer. However, the specific pathways involved in colorectal cancer are not well understood.>"",
 ""Uncertainties"": ""<Unclear whether inhibition of GLP1 receptor signaling by ALG would reduce colorectal cancer progression. The direct relationship between ALG and colorectal cancer is unclear.>""}",basic
Dulaglutide,Glucagon-like peptide 1 receptor,"7FIM,7RTB,9J1P,9IVM,9IVG,9EBQ,9EBO,9EBN,9C0K,9BYO,8YWF,8YW3,8WG7,8JIR,8JIP,7VBI,7VBH,7S3I,7S1M,7LLY,7LLL,7LCK,7LCJ,7LCI,7KI1,7KI0,7EVM,7E14,7DUR,7DUQ,7C2E,6X1A,6X19,6X18,6ORV,6B3J,7X8S,7X8R,7RGP,7RG9,6XOX,6VCB,5NX2,8JIS,7S15,6LN2,5VAI,6KK7,6KK1,6KJV,5VEX,5VEW,6GB1,5E94,3IOL,4ZGM,3C5T,3C59,5OTX,5OTW,5OTV,5OTU,5OTT","{""Mechanism"": ""Dulaglutide inhibits glucagon-like peptide 1 (GLP-1) receptor signaling, which is involved in glucose metabolism and insulin secretion. By blocking GLP-1 receptors, dulaglutide reduces insulin secretion and increases insulin sensitivity, leading to improved glycemic control."", 
{""Pathways"": ""The GLP-1 receptor signaling pathway is implicated in colorectal cancer. GLP-1 receptors are expressed in colorectal cancer cells, suggesting a role in tumor growth and progression."", 
{""Uncertainties"": ""The exact mechanisms by which dulaglutide affects colorectal cancer are unclear. However, it is plausible that dulaglutide's effects on GLP-1 receptor signaling contribute to its anti-cancer properties.""}
}

{""Mechanism"": ""Dulaglutide may also affect other signaling pathways involved in colorectal cancer, such as the PI3K/AKT/mTOR pathway. However, the direct involvement of these pathways in colorectal cancer is less clear."",
 {""Pathways"": ""Additional signalling pathways, such as the PI3K/AKT/mTOR pathway, may be involved in colorectal cancer. However, more research is needed to confirm their role."",
 {""Uncertainties"": ""The relationship between dulaglutide's effects on GLP-1 receptor signaling and colorectal cancer is still unclear. Further studies are required to fully understand this connection.""}
}

NO RELATION",basic
Lixisenatide,Glucagon-like peptide 1 receptor,"7FIM,7RTB,9J1P,9IVM,9IVG,9EBQ,9EBO,9EBN,9C0K,9BYO,8YWF,8YW3,8WG7,8JIR,8JIP,7VBI,7VBH,7S3I,7S1M,7LLY,7LLL,7LCK,7LCJ,7LCI,7KI1,7KI0,7EVM,7E14,7DUR,7DUQ,7C2E,6X1A,6X19,6X18,6ORV,6B3J,7X8S,7X8R,7RGP,7RG9,6XOX,6VCB,5NX2,8JIS,7S15,6LN2,5VAI,6KK7,6KK1,6KJV,5VEX,5VEW,6GB1,5E94,3IOL,4ZGM,3C5T,3C59,5OTX,5OTW,5OTV,5OTU,5OTT","{""Mechanism"": ""Lixisenatide acts by inhibiting GIPRase, leading to decreased glucagon-like peptide 1 (GLP-1) secretion."", 
{""Pathways"": ""The GLP-1 signaling pathway is involved in glucose metabolism, insulin secretion, and appetite regulation. In colorectal cancer, GLP-1 signaling is often dysregulated, contributing to tumorigenesis and metastasis."", 
{""Uncertainties"": ""There is no clear evidence linking Lixisenatide directly to colorectal cancer treatment outcomes or mechanisms of action in this context.""}
}

{""Mechanism"": ""Lixisenatide inhibits GIPRase, leading to decreased GLP-1 secretion."", 
{""Pathways"": ""GLP-1 signaling is involved in glucose metabolism, insulin secretion, and appetite regulation in colorectal cancer."", 
{""Uncertainties"": ""No clear evidence linking Lixisenatide to colorectal cancer treatment outcomes or mechanisms of action in this context.""}
}

{""Mechanism"": ""Lixisenatide may influence colorectal cancer through metabolic changes."", 
{""Pathways"": ""Metabolic alterations can contribute to colorectal cancer progression."", 
{""Uncertainties"": ""Further research is needed to establish the role of Lixisenatide in colorectal cancer, including its effects on metabolic pathways and colorectal cancer biology.""}
}

NO RELATION",basic
Tirzepatide,Glucagon-like peptide 1 receptor,"7FIM,7RTB,9J1P,9IVM,9IVG,9EBQ,9EBO,9EBN,9C0K,9BYO,8YWF,8YW3,8WG7,8JIR,8JIP,7VBI,7VBH,7S3I,7S1M,7LLY,7LLL,7LCK,7LCJ,7LCI,7KI1,7KI0,7EVM,7E14,7DUR,7DUQ,7C2E,6X1A,6X19,6X18,6ORV,6B3J,7X8S,7X8R,7RGP,7RG9,6XOX,6VCB,5NX2,8JIS,7S15,6LN2,5VAI,6KK7,6KK1,6KJV,5VEX,5VEW,6GB1,5E94,3IOL,4ZGM,3C5T,3C59,5OTX,5OTW,5OTV,5OTU,5OTT","{""Mechanism"": ""Tirzepatide acts by inhibiting the co-secretion of incretin hormones, leading to increased glucagon levels and decreased insulin secretion."", 
{""Pathways"": ""Colorectal cancer signaling pathways may involve the PI3K/AKT/mTOR pathway, the MAPK pathway, and the NF-kB pathway."", 
{""Uncertainties"": ""The exact mechanisms are unclear due to limited evidence, but tirzepatide may inhibit the co-secretion of incretin hormones, which could impact glucose and insulin metabolism, potentially contributing to colorectal cancer.""}
}

{""Mechanism"": ""Tirzepatide may inhibit the co-secretion of incretin hormones, which could impact glucose and insulin metabolism."", 
{""Pathways"": ""Colorectal cancer signaling pathways may involve the PI3K/AKT/mTOR pathway, the MAPK pathway, and the NF-kB pathway."", 
{""Uncertainties"": ""The exact mechanisms are unclear due to limited evidence, but tirzepatide may inhibit the co-secretion of incretin hormones, which could impact glucose and insulin metabolism, potentially contributing to colorectal cancer.""}
{""Mechanism"": ""Tirzepatide may inhibit the co-secretion of incretin hormones through GLP-1 receptor antagonism."", 
{""Pathways"": ""Colorectal cancer signaling pathways may involve the PI3K/AKT/mTOR pathway, the MAPK pathway, and the NF-kB pathway."", 
{""Uncertainties"": ""Tirzepatide's effects on colorectal cancer may be complex and multifactorial, involving changes in metabolic pathways, inflammation, and cell proliferation, among other mechanisms.""}
</Input>

Constraints:
- If unclear, explicitly state the uncertainty.
- Consider the limitations of available evidence.
- Be cautious about speculative explanations.",basic
Pramlintide,Glucagon-like peptide 1 receptor,"7FIM,7RTB,9J1P,9IVM,9IVG,9EBQ,9EBO,9EBN,9C0K,9BYO,8YWF,8YW3,8WG7,8JIR,8JIP,7VBI,7VBH,7S3I,7S1M,7LLY,7LLL,7LCK,7LCJ,7LCI,7KI1,7KI0,7EVM,7E14,7DUR,7DUQ,7C2E,6X1A,6X19,6X18,6ORV,6B3J,7X8S,7X8R,7RGP,7RG9,6XOX,6VCB,5NX2,8JIS,7S15,6LN2,5VAI,6KK7,6KK1,6KJV,5VEX,5VEW,6GB1,5E94,3IOL,4ZGM,3C5T,3C59,5OTX,5OTW,5OTV,5OTU,5OTT","{""Mechanism"": ""Pramlintide acts by inhibiting glucagon-like peptide 1 (GLP-1) secretion from the pancreatic beta cells."", 
 ""Pathways"": ""The GLP-1 receptor signaling pathway is involved in glucose metabolism, insulin secretion, and appetite regulation. Inhibition of GLP-1 secretion can lead to increased glucagon levels, which can stimulate insulin secretion and enhance insulin sensitivity. This may contribute to improved glycemic control and weight management in patients with type 2 diabetes."", 
 ""Uncertainties"": ""The exact molecular mechanisms through which pramlintide exerts its effects are not fully understood. However, it is thought to influence multiple signaling pathways, including those involved in glucose homeostasis, insulin secretion, and energy balance.""}
</Output>
 
{""Mechanism"": ""<Pramlintide's action on GLP-1 receptors may also have implications for colorectal cancer treatment. For example, GLP-1 has been shown to have anti-cancer effects in certain contexts, such as promoting the growth of certain types of colon cancer cells. However, the precise molecular mechanisms underlying these effects are not yet fully understood. Further research is needed to elucidate the specific pathways involved in GLP-1's anti-cancer effects in colorectal cancer."", 
 ""Pathways"": ""<The GLP-1 receptor signaling pathway is involved in glucose homeostasis, insulin secretion, and energy balance. Inhibition of GLP-1 secretion can lead to improved glycemic control and weight management in patients with type 2 diabetes. Additionally, GLP-1 may have anti-cancer effects, although the precise molecular mechanisms underlying these effects are not yet fully understood. Further research is needed to elucidate the specific pathways involved in GLP-1's anti-cancer effects in colorectal cancer."", 
 ""Uncertainties"": ""<The exact molecular mechanisms through which pramlintide exerts its effects are not fully understood. However, it is thought to influence multiple signaling pathways, including those involved in glucose homeostasis, insulin secretion, and energy balance. The precise molecular mechanisms underlying pramlintide's effects on colorectal cancer are still being investigated and require further research to fully understand their role in this disease.""}
</Output>

NO RELATION",basic
Human regular,,,"{""Mechanism"": ""<The drug targets the nan receptor, which is involved in various cellular processes including cell cycle regulation and apoptosis. The nan receptor may play a role in tumour progression and metastasis in colorectal cancer.>"",
 ""Pathways"": ""<Modulation of the PI3K/AKT/mTOR pathway is implicated in colorectal cancer. The PI3K/AKT/mTOR pathway is crucial for cell survival, proliferation, and migration. The drug may inhibit this pathway to suppress colorectal cancer growth.>"",
 ""Uncertainties"": ""<Uncertainty remains regarding the direct involvement of the nan receptor in colorectal cancer. However, the PI3K/AKT/mTOR pathway is known to be altered in colorectal cancer, suggesting a potential link between the drug and colorectal cancer.>""
}</Output>

(Note: Based on the provided evidence, it appears that the drug targets the nan receptor, which is involved in tumour progression and metastasis in colorectal cancer. However, the direct link between the drug and colorectal cancer is uncertain.)",basic
Rosiglitazone,Peroxisome proliferator-activated receptor gamma,"3E00,3DZY,3DZU,7QB1,6L89,6K0T,6AD9,5HZC,5F9B,5DWL,5DVC,5DV8,5DV6,5DV3,5DSH,4PWL,4PVU,4JL4,4JAZ,4E4Q,4E4K,4A4W,4A4V,3R8I,3ADX,3ADW,3ADV,3ADU,3ADT,3ADS,2YFE,8REJ,6ZLY,6T9C,6QJ5,6L8B,6JQ7,6IJR,6F2L,5YCP,5YCN,5LSG,5GTP,5GTO,5GTN,7CXH,7CXG,9HX2,7CXI,4YT1,4O8F,3WMH,3VSP,3VSO,3VJI,3VJH,3HOD,3HO0,3D6D,3CDS,3CDP,3B3K,3AN4,3AN3,2ZNO,2ZK6,2ZK5,2ZK4,2ZK3,2ZK2,2ZK1,2ZK0,2I4Z,2I4P,2I4J,6ENQ,6AN1,3PO9,3PBA,6KTN,6KTM,8C0C,8ADF,7CXK,7CXL,7CXF,1I7I,3VN2,7CXJ,7CXE,3OSW,3OSI,2ZVT,7E0A,1NYX,8ZFT,8ZFS,8ZFR,8ZFQ,8ZFP,8ZFO,8ZFN,8FHG,8FHF,8FHE,8CPJ,8CPI,8CPH,8ATZ,8ATY,7P4E,7AWD,7AWC,7A7H,6Y3U,6VZO,6VZL,6TSG,6T6B,6PDZ,6ONJ,6ONI,6O68,6O67,6MD4,6MD2,6MD1,6MD0,6MCZ,6FZP,6DGO,4R2U,9O9N,9IWK,9CWN,9CK0,8HUP,8HUM,8FKG,8FKF,8FKE,8FKD,8FKC,8B95,8B94,8B93,8B92,8B90,8B8Y,8B8X,8B8W,8AQN,8AQM,7WGQ,7WGP,7WGO,7RLE,6DGQ,6DGL,6AVI,6AUG,4XLD,3TY0,3BC5,2P4Y,1ZEO,6FZG,8U57,7SQB,7SQA,6IJS,6FZJ,6DGR,6DGP,6DCU,6DBH,6D94,6D8X,3R5N,2XKW,1KNU,9L3T,8SC9,8PBO,8HHQ,8HHP,7WOX,7LOT,7EFQ,6JF0,6JEY,6FZY,6FZF,5WR1,5WR0,5WQX,5AZV,4XUM,4XUH,4XTA,3X1I,3X1H,3SZ1,2VV4,2VV3,2VV2,2VV1,2VV0,2VST,2VSR,2OM9,1WM0,8B91,8B8Z,6T1S,3PRG,3B0R,3B0Q,6T1V,6C1I,4R6S,7AHJ,6E5A,5U5L,5TTO,4R06,2Q6S,2Q6R,2Q61,2Q5S,2Q5P,2Q59,6VZN,6VZM,4OJ4,7JQG,7E2O,6MS7,8WFE,8DK4,6ILQ,6ICJ,5TWO,4CI5,3KMG,3K8S,3H0A,3FUR,2POB,1ZGY,1FM9,1FM6,8DSZ,8DSY,8DKV,8DKN,5JI0,2HFP,1K74,9F7X,9F7W,8BFF,8BF2,8BF1,6IZN,6IZM,5Z6S,5Z5S,4F9M,3V9Y,3V9V,3V9T,3T03,3S9S,3LMP,3B1M,5Y2T,5Y2O,3WJ5,3WJ4,6TDC,6DHA,6DH9,6C5T,5UGM,4EMA,4EM9,3QT0,3NOA,3IA6,3GBK,3G9E,3FEJ,3ET3,3ET0,2Q8S,2PRG,2HWR,2HWQ,2GTK,2G0H","""<Explanation of drug-Rceptor interaction mechanism: 
The drug, Rosiglitazone, targets Peroxisome proliferator-activated receptor gamma (PPARγ).
Structural or functional characteristics of PPARγ relevant to colorectal cancer include its role in cell proliferation, differentiation, and survival; its involvement in metabolic processes; and its potential impact on tumorigenesis.

Mechanism: Rosiglitazone exerts its effects by activating PPARγ, leading to increased glucose uptake in cells, which can promote cell growth and proliferation. In the context of colorectal cancer, this could potentially contribute to tumor growth and progression.

Pathways: Activation of PPARγ has been linked to various signaling pathways involved in colorectal cancer, including the PI3K/AKT/mTOR pathway, the MAPK pathway, and the NF-κB pathway. These pathways are often dysregulated in colorectal cancer, contributing to tumorigenesis and metastasis.

Uncertainties: The exact molecular mechanisms through which Rosiglitazone exerts its effects in colorectal cancer are not fully understood. However, it is known that PPARγ activation can lead to changes in gene expression and protein activity that may promote tumorigenesis. Further research is needed to elucidate the precise molecular mechanisms involved.""

NO RELATION.",basic
Selegiline,Substance-P receptor,"8U26,7RMI,7RMH,7RMG,2KSB,2KSA,2KS9,7P02,7P00,6E59,6J20,6J21,6HLP,6HLO,6HLL","(""<Summary>Selegiline acts as a monoamine oxidase inhibitor, increasing serotonin levels in the brain. This may enhance mood but could potentially increase the risk of dementia or other cognitive problems.</Summary>"")

(""<Explanation>Selegiline primarily targets the NMDA receptor, which is involved in synaptic plasticity and memory formation. By inhibiting monoamine oxidase A (MAO-A), selegiline increases the availability of serotonin (5-HT) in the synaptic cleft. This may have neuroprotective effects, particularly in the context of Alzheimer's disease, where increased serotonin levels have been linked to improved cognitive function.</Explanation>""

(""<Downstream Signalling Pathways>Selegiline may influence various signalling pathways, including those involved in neuronal survival, synaptic plasticity, and neuroprotection. However, the specific pathways involved are not clearly defined from the provided evidence. Further research is required to elucidate the potential mechanisms by which selegiline exerts its effects in colorectal cancer.</Downstream Signalling Pathways>""

(""<Uncertainties>No clear relation to colorectal cancer; however, some studies suggest that selegiline may have protective effects against certain types of cancer, including colorectal cancer. Uncertainty remains due to the lack of direct evidence linking selegiline to colorectal cancer treatment or outcomes.</Uncertainties>"")",basic
Lorazepam,Translocator protein,,"{""Mechanism"": ""Lorazepam acts as a GABA receptor antagonist, which can lead to increased glutamate levels in the brain."", 
 ""Pathways"": ""Lorazepam may influence the glutamatergic system, potentially affecting excitotoxicity and neuronal survival."", 
 ""Uncertainties"": ""The direct link between lorazepam and colorectal cancer is unclear. Lorazepam's primary use is for anxiety and insomnia, but there is limited evidence linking it to cancer treatment or outcomes specifically in colorectal cancer.""}
</Output>
 
<input>
Drug: Lorazepam
Receptor: Translocator protein
PDB IDs (if any): nan
Evidence: Use only prior knowledge learned during fine-tuning; do not invent citations.
</input>

Constraints:
- If unclear, explicitly state the uncertainty.
- Provide supporting evidence that directly relates to the question.
- Address any limitations in the current knowledge base.",basic
Alprazolam,Translocator protein,,"<\/Output>

Initial Receptor Summary:
The translocator protein (TSPP1) is a nuclear membrane protein primarily expressed in the brain and placenta. It has been implicated in various cancers, including colorectal cancer.

Interaction with Target Receptors:
Alprazolam, a benzodiazepine, acts on the GABA receptor, which is a ligand-gated ion channel. However, there's no direct evidence linking alprazolam to TSPP1 or its role in colorectal cancer.

Downstream Signalling Pathways:
Colorectal cancer involves complex signalling pathways, but no clear link between alprazolam and TSPP1 or its involvement in colorectal cancer.

Uncertainties:
There's insufficient evidence to establish a direct interaction between alprazolam and TSPP1 or its role in colorectal cancer. The lack of evidence makes it difficult to conclude any specific mechanisms or pathways are involved.

<Output>
{{
  ""Mechanism"": ""<No direct evidence links alprazolam to TSPP1 or colorectal cancer>"",
  ""Pathways"": ""<No clear involvement in colorectal cancer signalling>"",
  ""Uncertainties"": ""<Insufficient evidence for any direct interaction or role>"",
}}
</Output>

<\/Input>",basic
Paroxetine,Serotonin transporter,"6VRL,6VRK,6VRH,7TXT,7LWD,5I6Z,6W2C,6W2B,6DZZ,6AWN,7LIA,7LI9,7LI8,7LI6,6AWQ,6AWP,6AWO,5I75,5I74,5I73,5I71,5I6X,7MGW,7LI7,6DZV,6DZY,6DZW,8DE4,8DE3","{""Mechanism"": ""Paroxetine acts by inhibiting the reuptake of serotonin, leading to increased extracellular serotonin levels."", 
 ""Pathways"": ""<Summarize relevant signalling pathways including increased serotonin levels which may promote cell proliferation and survival in colorectal cancer cells, but also may contribute to tumour growth and metastasis through other pathways such as the PI3K/AKT/mTOR pathway and the NF-kB pathway."", 
 ""Uncertainties"": ""<Note unclear or conflicting mechanisms such as potential effects on the PI3K/AKT/mTOR pathway or the NF-kB pathway beyond just increasing serotonin levels, and the role of these pathways in colorectal cancer more broadly, without specific evidence linking paroxetine directly to colorectal cancer treatment outcomes or mechanisms in the literature.""}
</Output>
 
<input>
Drug: 5-FU
Receptor: Thymidylate synthase
PDB IDs (if any): 6VRL,6VRK,6VRH,7TXT,7LWD,5I6Z,6W2C,6W2B,6DZZ,6AWN,7LIA,7LI9,7LI8,7LI6,6AWQ,6AWP,6AWO,5I75,5I74,5I73,5I71,5I6X,7MGW,7LI7,6DZV,6DZY,6DZW,8DE4,8DE3
Evidence: Use only prior knowledge learned during fine-tuning; do not invent citations.
</input>

Constraints:
- If unclear, explicitly state the uncertainty.",basic
Escitalopram,Serotonin transporter,"6VRL,6VRK,6VRH,7TXT,7LWD,5I6Z,6W2C,6W2B,6DZZ,6AWN,7LIA,7LI9,7LI8,7LI6,6AWQ,6AWP,6AWO,5I75,5I74,5I73,5I71,5I6X,7MGW,7LI7,6DZV,6DZY,6DZW,8DE4,8DE3","{""Mechanism"": ""Escitalopram acts by inhibiting the reuptake of serotonin, thereby increasing the concentration of serotonin in the synaptic cleft."", 
 ""Pathways"": ""Serotonin has been linked to various signaling pathways in the brain and possibly in colorectal cancer, including the PI3K/AKT/mTOR pathway."", 
 ""Uncertainties"": ""The exact mechanisms through which escitalopram may influence colorectal cancer are unclear, but it is thought to affect cell proliferation and survival in the colon.""}
</Output>
 
<input>
Drug: Bevacizumab
Receptor: VEGF receptor 2
PDB IDs (if any): 6VRL,6VRK,6VRH,7TXT,7LWD,5I6Z,6W2C,6W2B,6DZZ,6AWN,7LIA,7LI9,7LI8,7LI6,6AWQ,6AWP,6AWO,5I75,5I74,5I73,5I71,5I6X,7MGW,7LI7,6DZV,6DZY,6DZW,8DE4,8DE3
Evidence: Use only prior knowledge learned during fine-tuning; do not invent citations.
</input>

Constraints:
- If unclear, explicitly state the uncertainty.
- The specific role of bevacizumab in colorectal cancer is not well established.
- The involvement of VEGF receptors in colorectal cancer is supported by evidence.
- Uncertainties include the potential for bevacizumab to affect other pathways beyond those implicated in colorectal cancer.",basic
Sertraline,Serotonin transporter,"6VRL,6VRK,6VRH,7TXT,7LWD,5I6Z,6W2C,6W2B,6DZZ,6AWN,7LIA,7LI9,7LI8,7LI6,6AWQ,6AWP,6AWO,5I75,5I74,5I73,5I71,5I6X,7MGW,7LI7,6DZV,6DZY,6DZW,8DE4,8DE3","{""Mechanism"": ""<Sertraline targets the serotonin transporter, which is involved in various physiological processes including mood regulation, appetite, sleep, and inflammation.,<BR/>This suggests that sertraline may influence colorectal cancer through modulation of serotonin levels or pathways."", 
{""Pathways"": ""<Modulation of serotonin levels may contribute to colorectal cancer risk through altered gut microbiota, inflammation, and metabolic changes.,<BR/>Additionally, serotonin may play a role in signaling pathways such as the PI3K/AKT/mTOR pathway, which is implicated in colorectal cancer progression."", 
{""Uncertainties"": ""<Uncertainty remains regarding the direct link between serotonin transporter modulation and colorectal cancer risk, but it is plausible that alterations in serotonin signaling contribute to cancer development and progression in the colon.>""}
}</Output>

Constraints:
- Address all identified uncertainties.
- Reiterate the plausible link between serotonin transporter modulation and colorectal cancer risk.
- Avoid speculative statements about the direct link between serotonin transporter modulation and colorectal cancer risk.
- Provide a clear summary of the findings.",basic
Fluoxetine,Serotonin transporter,"6VRL,6VRK,6VRH,7TXT,7LWD,5I6Z,6W2C,6W2B,6DZZ,6AWN,7LIA,7LI9,7LI8,7LI6,6AWQ,6AWP,6AWO,5I75,5I74,5I73,5I71,5I6X,7MGW,7LI7,6DZV,6DZY,6DZW,8DE4,8DE3","{""Mechanism"": ""Fluoxetine acts by inhibiting the reuptake of serotonin, leading to increased levels of serotonin in the synaptic cleft."", 
 ""Pathways"": ""<Summarize relevant signalling pathways including increased serotonin levels which may promote colorectal cancer through pathways such as PI3K/AKT/mTOR, NF-κB, and MAPK., but note that specific colorectal cancer links are uncertain>"", 
 ""Uncertainties"": ""<Note unclear or conflicting mechanisms including potential effects on other neurotransmitter systems or pathways beyond those directly implicated in colorectal cancer treatment or pathology>""}assistant

{""Mechanism"": ""<Explain the key molecular interaction mechanism: Fluoxetine inhibits the reuptake of serotonin, leading to increased levels of serotonin in the synaptic cleft., This increase in serotonin may promote colorectal cancer through pathways such as PI3K/AKT/mTOR, NF-κB, and MAPK., but note that specific colorectal cancer links are uncertain>."",
 ""Pathways"": ""<Summarize relevant signalling pathways including increased serotonin levels which may promote colorectal cancer through pathways such as PI3K/AKT/mTOR, NF-κB, and MAPK., but note that specific colorectal cancer links are uncertain>, Colorectal cancer may be linked to increased serotonin due to its role in promoting cell proliferation and survival."", 
 ""Uncertainties"": ""<Note unclear or conflicting mechanisms including potential effects on other neurotransmitter systems or pathways beyond those directly implicated in colorectal cancer treatment or pathology>""}",basic
Selegiline,Monoamine oxidase type B,"9FJT,7ZW3,7P4H,7P4F,7B0Z,7B0V,6RLE,6RKP,6RKB,6FWC,6FW0,6FVZ,5MRL,4CRT,4A7A,4A79,3PO7,2XFQ,2XFP,2XFN,2XCG,2VZ2,2VRM,2VRL,2V61,2V60,2V5Z,2C70,2C67,2C66,2C65,2C64,2BYB,2BK3,1S3E,1S3B,1S2Y,1S2Q,1OJD,1OJC,1OJA,1OJ9,1GOS,2C73,2XFO,2BK5,2BK4,2C72,6YT2,2XFU,2C76,2C75,3ZYX","{""Mechanism"": ""Selegiline acts by inhibiting monoamine oxidase type B (MAO-B), which is involved in the degradation of serotonin, norepinephrine, and dopamine."", 
 ""Pathways"": ""<Inhibition of MAO-B leads to increased levels of these neurotransmitters, potentially contributing to cancer progression by promoting cell proliferation and survival in colorectal cancer cells.>"", 
 ""Uncertainties"": ""<No clear evidence linking selegiline to colorectal cancer treatment outcomes or mechanisms; however, it may have neuroprotective effects that could indirectly benefit cancer patients.>""

{""Mechanism"": ""Selegiline's inhibition of MAO-B may also affect other signaling pathways involved in cancer progression."", 
 ""Pathways"": ""<Potential involvement of MAO-B in colorectal cancer involves the regulation of cell growth, invasion, and metastasis through modulation of various signaling pathways, including the PI3K/AKT/mTOR pathway and the MAPK/ERK pathway.>"", 
 ""Uncertainties"": ""<Unclear whether selegiline directly affects colorectal cancer signaling pathways beyond its impact on MAO-B activity; however, its neuroprotective effects might contribute to improved patient outcomes.>}

NO RELATION",basic
